Opto Biosystems develops implantable neural devices that measure and disrupt electric fields in the body, providing real-time biomarkers and diagnostic insights for aggressive cancers. Their technology aims to enhance treatment efficacy and patient outcomes by integrating bioelectronic medicine with cancer neuroscience.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Aggressive cancers are difficult to treat, with low survival rates and limited improvements from new drugs. Current diagnostic methods lack real-time biomarkers and insights into the electrical activity within tumors, hindering the development of more effective therapies.
Solution
Opto Biosystems is developing implantable neural devices that measure and modulate electric fields in the body to provide real-time biomarkers and diagnostic insights for aggressive cancers. By uniting cancer neuroscience and bioelectronic medicine, their technology aims to enhance treatment efficacy and patient outcomes. The SOMA-1 device combines electrical stimulation with electrical recording, offering a new approach to cancer treatment by capturing previously inaccessible data. This allows for the potential to revolutionize treatment for some of the most aggressive diseases.
Target Audience
The primary target audience includes oncologists, cancer researchers, and medical professionals seeking advanced diagnostic and therapeutic tools for aggressive cancers.
Features
- Implantable device capable of measuring electric fields within the body.
- Electrical stimulation capabilities for modulating neural activity in tumors.
- Real-time biomarkers and diagnostic insights through electrical recording.
- Minimally invasive neural interfaces for oncology applications.